CD274 and non-small cell lung carcinoma: The IMpower150 trial explored the combination of the anti-PD-L1 agent atezolizumab, the angiogenic inhibitor bevacizumab, and chemotherapy (carboplatin and paclitaxel) in the first-line treatment of advanced non-small-cell lung cancer.